Research Article

Acupuncture Effect Assessment in APP/PS1 Transgenic Mice: On Regulating Learning-Memory Abilities, Gut Microbiota, and Microbial Metabolites

Bo Yang, Min He, Xinhua Chen, Mengmeng Sun, Ting Pan, Xiaohong Xu, Xuesong Zhang, Qing Gong, Ye Zhao, Ziqi Jin, and Zedong Cheng

1Liaoning University of Traditional Chinese Medicine, No. 79, Chongshan Eastern Rd, Huanggu District, 110847 Shenyang, China
2Changchun University of Chinese Medicine, No. 1035, Boshuo Rd, Jingyue Economic Development District, 130117 Changchun, China
3Northwest University, No. 229, Taibai North Road, Xi'an 710069, China

Correspondence should be addressed to Zedong Cheng; chengzd05@163.com

Bo Yang and Min He contributed equally to this work.

Received 25 January 2022; Accepted 2 March 2022; Published 8 April 2022

Academic Editor: Min Tang

Copyright © 2022 Bo Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alzheimer’s disease (AD) is a brain illness that affects learning and memory capacities over time. In recent investigations, acupuncture has been shown to be an effective alternative treatment for AD. We investigated the effect of acupuncture on learning and memory abilities using a water maze in APP/PS1 transgenic mice. The amounts of Aβ and tau protein in mice’s hippocampal tissue were determined using Western blot. The levels of IL-1β, IL-10, LPS and TNF-α in mice’s serum were measured using ELISA. The variations of gut microbiota in mice’s feces were determined using the 16SrDNA technique, and the metabolites were examined using a untargeted metabolomics methodology. The results showed that acupuncture treatment improved mice’s learning and memory abilities substantially. Acupuncture therapy regulated the Aβ and tau protein concentration as well as the levels of IL-10 and LPS. Acupuncture treatment in fluenced the mouse microbiota and metabolites and had been linked to six biochemical pathways. This study adds to our understanding of the effect of acupuncture on AD and opens the door to further research into the alterations of intestinal bacteria in the presence of AD.

1. Introduction

Alzheimer’s disease (AD) is a slow-moving neurodegenerative disorder characterized by memory decline, cognitive impairment, and changes in personality. The major neuropathological conditions for the diagnosis of AD are the accumulation of extracellular amyloid β-protein (Aβ) as neuroinflammatory plaques and the accumulation of high phosphorylate tau intracellular protein as neurofibrillary tangles [1]. AD is the fourth leading cause of death for people over 65 years of age globally and has become a national public health concern [2]. There is no appropriate cure for AD [3–5], which can only marginally alleviate symptoms such as cognitive control and everyday physical dysfunction, cannot alter the underlying neuropathology or its development, and has some side effects [6–9]. AD patients can lose their capacity to live independently, placing immense pressures on family members, caregivers, and community as a whole. Annual health care costs associated with AD are estimated to be close to 500 billion US dollars [10]. A number of new biological technologies (e.g., genomics, proteomics, and metabolomics) have started to be used in AD research field [11–13]. More and more experiments have demonstrated in recent years that gut microbiota plays an important role in the management of human health and disease through sustaining intestinal homeostasis. [14, 15]. Gut microbiota
disorder is linked with multiple disorders, including gastrointestinal diseases [16–19] and AD [20–22]. Gut microbiota has a direct impact on AD, for example, helicobacter pylori enhances tau protein hyperphosphorylation [23]; intestinal disorders can encourage amyloid aggregation, neuroinflammation, oxidative stress, and insulin tolerance in AD pathogenesis [22]; and changes in the composition of gut microbiota can increase the release of lipopolysaccharides (LPSs) and amyloid, which may promote AD pathogenesis [24]. In addition, more and more comparative studies have shown that there are variations in gut microbiota composition between AD patients and healthy people, AD also leads to changes in gut microbiota or is associated with changes in gut microbiota [25–27]. As science offers data and broadens our understanding of AD pathogenesis, the study of gut microbiota provides further opportunities for diagnosis and treatment of AD.

In the meantime, due to the widespread distribution of AD cases globally, more and more complementary and alternative treatments are being used for the care and control of AD [28, 29]. Acupuncture is a common treatment that has been used in the whole world. It is based on the theory and concepts of Chinese medicine and it is healthy, economical, and comfortable and has few side effects [30]. Currently, acupuncture therapy has been commonly used in the care of different diseases, such as pain [31], stroke [32], asthma [33], and gastroenteritis [34]. The use of acupuncture to relieve different symptoms has drawn the interest of scientists all over the world. According to current research findings, the overall regulatory effect of acupuncture on AD can be accomplished by controlling irregular expression of proteins in the brain, by regulating the physiological and pathological status of microglia, mitochondrial autophagy, epigenetic alteration, oxidative activity, and energy metabolism and by enhancing synaptic plasticity [35]. In comparison, acupuncture is usually integrated which is multilayered and is a systematic and holistic therapy approach that is close to the omics methodology. Omics methods, including proteomics and metabolomics, have been successfully used to screen for disease biomarkers, which is an important technology that makes the acupuncture revolution an important driving force in practice. At present, the study between acupuncture and AD focuses on the rules of acupoint selection and the therapeutic process, and identification indices primarily concentrate on Aβ and tau protein, associated inflammatory factors, dietary factors, neurotransmitters, etc. However, it is important to further investigate whether acupuncture can cure AD, and the biomedical evidence for the treatment of AD. There have been recent research relating the effects of acupuncture to improvements in gut microbiota, investigating the regulatory effects of acupuncture, moxibustion, and electroacupuncture on obesity and ulcerative colitis [36–38], which suggest that gut microbiota could be a potential goal for the therapeutic impact of acupuncture. Therefore, researching the effects of acupuncture combined with controlling the gut microbiota and in vivo treatment of AD may provide a new perspective for understanding acupuncture treatment of AD.

In this research, acupuncture was used to treat APP/PS1 transgenic mice, which were used as an AD model. Water maze experiments revealed that acupuncture therapy improved the learning and memory capability of the APP/PS1 mice. Acupuncture therapy also had an important effect on the abundance changes of gut microbiota and metabolites of the APP/PS1 mice. Our results suggest that acupuncture, as a holistic approach, has great promise in the treatment and management of AD. This study encourages further research into the effects of acupuncture on variations in the intestinal microbiome associated with AD.

2. Materials and Methods

2.1. Animals. As AD models, eight-month-old APP/PS1 double-transgenic mice were employed. This animal encodes a number of human AD genes, exhibits common clinical symptoms of AD, and is widely acknowledged in the pathophysiology of cognitive impairment [39, 40]. Because it is more precise, trustworthy, and effective, the transgenic AD mouse model is commonly utilized to replace the classic AD model [41]. Furthermore, at 7-8 months of age, these mice showed brain Aβ deposition [42, 43] and loss of local neurons [44], as well as learning and memory problems [45]. Shanghai Model Organisms provided eight-month-old APP/PS1 double-transgenic male mice. (Certificate number: SCXK (Ji) 2019-0008). The APP/PS1 mice (weighing 30 ± 2 g) were randomly divided into three groups: model (M), acupuncture (A), and memantine (ME), each with eight mice. The normal control (C) group consisted of six C57BL/6 male mice. To reduce external interference, mice were housed separately in standard mouse cages under constant temperature (23 ± 2°C) and constant humidity (40%-60%), with free access to water and food. The study was conducted in strict accordance with the regulations of the Animal Ethics Committee (20200811-01). Throughout the experiment, we made every effort to minimize animal suffering.

2.2. Acupuncture Treatment. For a period of four weeks, the mice in acupuncture treatment group received acupuncture treatment for 20 minutes per day, five days per week, with two days off. Acupuncture points prescribed included Baihui (DU20), Hegu (LI4), Feishu (BL13), Pishu (BL20), Shenshu (BL23), Zusanli (ST36), and Sanyinjiao (SP6), as shown in Figure 1. The needles (diameter, 0.3 mm, Huatuo acupuncture of Suzhou Co., Ltd., Suzhou China) were inserted at a specific depth into corresponding acupoints.

2.3. Morris Water Maze (MWM) Test. After four weeks of acupuncture treatment, the mice’s spatial learning and memory capacities were tested using the MWM test, as previously described [46]. The MWM device consists of a black circular tank (120 cm in diameter) filled with water (temperature 22-24°C) and a platform (12 cm in diameter) located 1 cm below the water surface in the platform quadrant. Mice were randomly assigned to one of the four quadrants facing the maze wall, where they can find a platform. If the platform was not discovered within 60 seconds, it would be
follows the procedure, the blood obtained from decapitated mice was transferred to anticoagulant test tubes. After 2 hours at room temperature, the blood samples were centrifuged at 1000 rpm for 20 minutes, then we collected serum, and measured the levels of interleukin 1 beta (IL-1β) (ELISA Kit H002, Nanjing Jincheng Bioengineering Institute), interleukin 10 (IL-10) (ELISA Kit H009, Nanjing Jincheng Bioengineering Institute), lipopolysaccharides (LPS) (ELISA Kit A-054-2-1, Nanjing Jincheng Bioengineering Institute), and tumor necrosis factor alpha (TNF-a) (ELISA Kit H052, Nanjing Jincheng Bioengineering Institute) using an ELISA kit according to the manufacturer’s instructions.

2.5. Western Blot Analysis. Western blot (WB) was used to detect beta-amyloid 1-42 (Aβ) deposits and tau proteins expression in brain tissue samples. With a few exceptions, WB analysis was performed in accordance with conventional methods [47]. In brief, RIPA Lysis Buffer was used to lyse the total protein from each mouse hippocampal tissue sample, as directed by the manufacturer (Beyotime Institute of Biotechnology). The Bradford technique was used to determine the protein concentration. SDS-PAGE (8, 12, or 15% gel) was used to separate 20 g of protein, which was then transferred to the PVDF membrane. After 2 hours of blocking at room temperature with 5% skimmed milk, the membrane was incubated with particular primary antibodies overnight at 4°C. The primary antibodies utilized in this work were anti-beta-actin antibody (cat no. 25524-2-AP; 1:1000, Proteintech Group, Inc.) and anti-tau antibody (cat no. 66499-1-lg; 1: 10000; Proteintech Group, Inc.). The secondary antibody from the same genus was incubated at room temperature for 1.5 hours. Improved chemiluminescence detection reagent was used to improve imprinting detection (Beyotime Institute of Biotechnology). Image lab software can be used to evaluate and analyze band strength (Media Cybernetics, Inc., Rockville, MD, USA). The quantitative results were reported as a ratio of Aβ to β-actin and tau to β-actin and compared within each group to determine the relative changes.

2.6. DNA Extraction and 16SrDNA Gene Sequencing. The intestinal contents of mice were collected in a single sterile EP tube and immediately frozen at 80°C until DNA extraction was performed. The chloroform phenol DNA extraction method was used to extract the DNA from fecal samples. Thermo Nanodrop 2000 was used to determine the concentration of extracted DNA, and agarose gel electrophoresis was used to determine the molecular size. The V3-V4 region was then targeted using polymerase chain reaction amplification and 16SrDNA gene pyrosequencing. The Illumina Miseq platform was used to sequence the amplicon sequencing library, and the paired end read was 250 bp. The differences of bacterial abundance and diversity among different groups were analyzed by the Venn diagram, alpha diversity index, principal component analysis (PCA) etal., and so on in order to study the bacterial differences among groups at each classification level, ANOVA analysis of variance was used.

2.7. Microbial Function Analysis. Using the 16SrDNA gene database, Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) of the community was carried out by reconstructing the unobserved state to predict the functional composition of the microbial community [48]. The related predicted genes and their functions were compared with the Kyoto Encyclopedia of Genes and Genomes (KEGG) database [49], and the differences between groups were compared using the STAMP software [50].

2.8. Metabolomics Analysis. Metabolomics analysis was performed with liquid Chromatography-Quadrupole time of...
flight-mass spectrometry (LC-QTOF-MS, Waters, Shanghai, China) using an untargeted approach. Mouse feces samples (50 mg) were extracted with 80% methanol (800 μL). The extract was sonicated for 30 minutes at 4°C, and centrifuged for 15 minutes at 4°C, 12000 rpm, and then removed for 200 μL supernatant sparing. Chromatographic separations were performed on an Acquity HSS T3 column (2.1 × 1.8 μm, Waters, Mississauga, ON, Canada) using a gradient programming of MS-grade water containing 0.05 percent formic acid (A) and acetonitrile (B). The mobile phase flow rate was 0.3 mL/min, the column temperature was 40°C, the injection volume was 3 μL, and the temperature of the automated sampler was 4°C, the procedure is shown in Table 1. The eluted metabolites were analyzed in both positive and negative electrospray ionization mode with a full-scan ranging from 70 to 1050 m/z. All the raw files were first converted to mzML files by the ProteoWizard version 3.0 (Pala Alto, CA, USA), and data was processed for peak detection, retention time correction, alignment, and molecular feature annotation using the XCMS online version 3.7.1.

2.9. Statistics Analysis. The mean and standard deviation were used to represent the data. The SPSS 20.0 was used for statistical analysis, which included one-way ANOVA and the Student’s t-test. A statistically significant difference was defined as p < 0.05.

PCA and Partial least squares-discriminant analysis (PLS-DA) were used to discriminate among the identified microbial metabolites using the tools provided in the MetaboAnalyst 5.0. The PLS-DA model was validated using cross-validation in order to avoid overfitting of the model. Variable Importance in the Project (VIP) scores based on the PLS-DA analysis were used to indicate the metabolites which significantly contributed to group separation. Pathway analysis tool provided in the MetaboAnalyst 5.0 was used to study the KEGG pathways among metabolites with VIP scores > 1.2.

### 3. Results

#### 3.1. Acupuncture’s Effect on the Spatial Learning Abilities of APP/PS1 Mice.

MWM test was performed on the fifth day to investigate the effect of acupuncture on spatial memory ability of the APP/PS1 mice. When the platform was removed, the mice’s escape latency to the platform quadrant (Figure 2(e)), the average speed (Figure 2(f)), the quadrant frequency (Figure 2(g)), and the percentage of time spending in the platform quadrant were tested (Figure 2(h)). The escape latency of the APP/PS1 model group was the longest, which was significantly higher than that of the control group (p < 0.05). The escape latency of acupuncture treatment group did not vary significantly from the APP/PS1 model group and control group, respectively. However, the escape latency of acupuncture treatment group was closer to that of the control group (Figure 2(e)), suggesting that acupuncture could shorten the escape latency of the APP/PS1 mice.

#### 3.2. Acupuncture’s Effect on the Spatial Memory Abilities of APP/PS1 Mice.

MWM test was performed on the fifth day to investigate the effect of acupuncture on spatial memory ability of the APP/PS1 mice. When the platform was removed, the mice’s escape latency to the platform quadrant (Figure 2(e)), the average speed (Figure 2(f)), the quadrant frequency (Figure 2(g)), and the percentage of time spending in the platform quadrant were tested (Figure 2(h)). The escape latency of the APP/PS1 model group was the longest, which was significantly higher than that of the control group (p < 0.05). The escape latency of acupuncture treatment group did not vary significantly from the APP/PS1 model group and control group, respectively. However, the escape latency of acupuncture treatment group was closer to that of the control group (Figure 2(e)), suggesting that acupuncture could shorten the escape latency of the APP/PS1 mice.

| Time (min) | Flow rate (mL/min) | A (%) | B (%) |
|-----------|-------------------|-------|-------|
| 0         | 0.3               | 95    | 5     |
| 1         | 0.3               | 95    | 5     |
| 12        | 0.3               | 5     | 95    |
| 13.5      | 0.3               | 5     | 95    |
| 13.6      | 0.3               | 95    | 5     |
| 16        | 0.3               | 95    | 5     |

3.3. Acupuncture May Regulate Aβ and Tau Protein Expression in the Hippocampus of APP/PS1 Mice.

The accumulation of Aβ in the brain is thought to be the main feature of AD [24]. Amyloid plaques in the hippocampus can cause neuronal loss and cognitive dysfunction [21, 25]. The effect of acupuncture on Aβ deposition was investigated further in this research. WB analysis showed that the amount of Aβ in the APP/PS1 model group’s hippocampus tissue increased, and acupuncture treatment was able to reduce this increase significantly (p < 0.05, Figures 3(a) and 3(b)). Tau protein accumulation and the presence of neurofibrillary
Tangles were more closely related to symptom severity and neuron death in humans than Aβ lesions [51]. According to our findings, the acupuncture treatment group’s expression of tau protein in the hippocampus was lower as compared to the model group, but there was no substantial difference between the two groups. In addition, the acupuncture treatment group’s therapeutic effects on the expression of Aβ and tau protein were also similar to that of the positive control group. These findings suggested that acupuncture could regulate the expression of Aβ and tau protein in the APP/PS1 mice.

3.4. Acupuncture Regulates Inflammatory Factors in APP/PS1 Mice. Many findings suggested that neuroinflammation plays a key role in the development of the neuropathological changes seen in AD [52]. In our research, ELISA was used to detect the expressions of IL-1β, IL-10, LPS, and TNF-α in
The mice’s serum (Figures 4(a)–4(d)). Our findings indicated that there was no significant difference in the IL-10 expression between the control and model groups, but the IL-10 expression of the model group’s rose in comparison to the control group. Meanwhile, when compared to the model group, the positive control group and acupuncture treatment...
group had significantly lower IL-10 levels \( (p < 0.01, \text{Figure } 4(a)) \), showing that acupuncture may have a regulatory influence on the level of IL-10 in the APP/PS1 mice. In addition, acupuncture treatment reduced LPS in the mice’s serum significantly \( (p < 0.05, \text{Figure } 4(c)) \). However, there was no significant difference in IL-1\( \beta \) and TNF-\( \alpha \) expression among the four groups (Figures 4(b) and 4(d)).

### 3.5. Acupuncture Regulates the Gut Microbiota of APP/PS1 Mice

Since the aforementioned studies had demonstrated that the therapeutic effect of acupuncture was close to that of positive drug, however, the primary goal of this research was the effect of acupuncture, we excluded the positive drug group from the gut microbiota and metabolites research and studied the gut microbiota composition among the control group, APP/PS1 model group, and acupuncture treatment group in this section.

We used 16srDNA detection on the feces of the mice to investigate the impact of acupuncture on the gut microbiota. A total of 672 operational taxonomic units (OTUs) were displayed at a 97 percent similarity level. The Venn diagram revealed that the three groups shared 327 OTUs, with 85 OTUs unique to the control group, 40 OTUs unique to the APP/PS1 model group, and 30 OTUs unique to the acupuncture treatment group (Figure 5(a)). On the rarefaction curve, the number of organisms observed increased as the amount of sequencing data increased. When a certain amount of sequencing data was reached, the rarefaction curve exhibited a relatively stable condition, suggesting that the amount of sequencing data of samples was reasonable (Figure 5(b)). According to the Shannon and Simpson indices (Figures 5(c) and 5(d)), the APP/PS1 mice had lower gut microbiota diversity, and acupuncture appeared to regulate gut microbiota diversity; however there was no statistical difference \( (p > 0.05) \). Figure 6 illustrates the phylum-level variations and relative abundance of the three groups. Bacteroidetes and Firmicutes had the highest relative abundance (Figure 6(a)). The APP/PS1 model group and acupuncture treatment group varied greatly from the control group, and there was no statistically significant
difference between the model and acupuncture treatment
groups (Figure 6(b)). Actinobacteria varied among the three
groups. The APP/PS1 model group varied substantially from
the control and acupuncture treatment groups ($p < 0.05$),
but there was no difference between the control and acu-
puncture treatment groups (Figure 6(b)). To explore the dif-
fferences in gut microbiota among the three groups further,
we performed PCA analysis of the microbiota of each group
to visualize the differences. Figure 6(c) demonstrates the
PCA results as a score graph. The variance of the two prin-
cipal components (axis 1 and axis 2) in the mouse OTU data
was found to account for 51.942 percent and 17.357 percent
of the overall variance, respectively. The results revealed
three independent clusters clearly among groups.

Following that, we used the LDA Effect Size (LEfSe)
analysis on the I-Sanger platform to classify the communi-
ties in the study. LEfSe can be compared across several clas-
tes to classify bacterial species with major abundance
differences. Figure 7 depicts the differences in the bacterial
taxa of mice among the three groups. The diameter of the
circle represented the species’ abundance. The radial circles
reflected the classification level from phylum to species,
from inside to outside (phylum-class-order-family-genus-
species). A classification was defined by each small circle
on a different classification stage. The small circle’s diameter
was proportional to its relative abundance. The degree of
species annotation was defined by the fan-shaped region
drawn from the inside to the outside. The color of the gut
microbiota varies, and species that were not distinct had to
be colored yellow. The red node represented a microbial
group that was important in the control group, the green
node represented a microbial group that was important in
the APP/PS1 model group, and the blue node represented
a microbial group that was important in the acupuncture

difference between the model and acupuncture treatment
groups (Figure 6(b)). Actinobacteria varied among the three
groups. The APP/PS1 model group varied substantially from
the control and acupuncture treatment groups ($p < 0.05$),
but there was no difference between the control and acu-
puncture treatment groups (Figure 6(b)). To explore the dif-
fferences in gut microbiota among the three groups further,
we performed PCA analysis of the microbiota of each group
to visualize the differences. Figure 6(c) demonstrates the
PCA results as a score graph. The variance of the two prin-
cipal components (axis 1 and axis 2) in the mouse OTU data
was found to account for 51.942 percent and 17.357 percent
of the overall variance, respectively. The results revealed
three independent clusters clearly among groups.

Following that, we used the LDA Effect Size (LEfSe)
analysis on the I-Sanger platform to classify the communi-
ties in the study. LEfSe can be compared across several clas-
tes to classify bacterial species with major abundance
differences. Figure 7 depicts the differences in the bacterial
taxa of mice among the three groups. The diameter of the
circle represented the species’ abundance. The radial circles
reflected the classification level from phylum to species,
from inside to outside (phylum-class-order-family-genus-
species). A classification was defined by each small circle
on a different classification stage. The small circle’s diameter
was proportional to its relative abundance. The degree of
species annotation was defined by the fan-shaped region
drawn from the inside to the outside. The color of the gut
microbiota varies, and species that were not distinct had to
be colored yellow. The red node represented a microbial
group that was important in the control group, the green
node represented a microbial group that was important in
the APP/PS1 model group, and the blue node represented
a microbial group that was important in the acupuncture

Figure 6: Microbial composition structures at the phylum level of mice in the three groups. (a) Amounts of relative abundance (%) of bacterial taxa at the phylum level. (b) Significantly different bacterial taxa at the phylum level of mice in the three groups. *p < 0.05; **p < 0.01. (c) PCA results of beta diversity calculated of mice’s OTU data among the three groups. C: control group; M: APP/PS1 model group; A: acupuncture treatment group.
treatment group. The cladogram revealed 62 taxa (9 classes, 9 orders, 19 families, and 25 genera) that differed in abundance among the three groups. Figure 8 depicts the LDA scores of the three groups with major differences, which were determined by selecting the top ten species in each group with the lowest p value from the LEfSe results. The length of the bar graph reflected the contribution of individual bacteria for the classification among different groups.

Next, we explored the gut microbiota variations among the three groups at the family stage. Figure 9(a) depicts the relative abundance of Porphyromonadaceae, Helicobacteraceae, and Burkholderiaceae among the three groups at the family stage. Figure 9(b) and 9(c)). In addition, acupuncture therapy reduced significantly the relative abundance of Porphyromonadaceae (p < 0.05), Coriobacteriaceae (p < 0.05), Helicobacteriaceae (p < 0.05), and Burkholderiaceae (p < 0.01) of the APP/PS1 mice (Figure 9(b)). Moreover, acupuncture treatment was able to increase significantly the relative abundance of Christen- senellaceae (p < 0.01), Clostridiaceae 1 (p < 0.01), Prevotellaceae (p < 0.05), Rikenellaceae (p < 0.05), and Bacteroidaceae (p < 0.05) of the APP/PS1 mice (Figure 9(c)). Furthermore, there was a statistically significant difference in Lactobacillaceae between the APP/PS1 model and control group (p < 0.001). The difference was more distinct between the acupuncture treatment and control group (p < 0.0001). The relative abundance of Lactobacillaceae was able to increase by acupuncture, indicating an inverse tendency compared to the control group.

Following that, we used PICRUSt to examine and predict the functional gene composition in the metabolic pathway. To identify the functional genes with significant differences, ANOVA was used to compare the relative abundance of functional genes among the three classes. The screening threshold for substantial differences was set at p < 0.05. The metabolic pathway prediction was created for functional

**Figure 7:** Cladograms generated by LEfSe indicating differences in the bacterial taxa of mice among the three groups. C: control group; M: APP/PS1 model group; A: acupuncture treatment group.
3.6. Acupuncture Regulates the Microbial Metabolites of APP/PS1 Mice. A total of 697 metabolites were detected in the fecal extract samples after peak filtering and blank subtraction. Multivariate statistical analyses were carried out using the MetaboAnalyst 5.0 to reveal the changes in metabolite among groups in the 697 compounds results. The variations in metabolic profiles between the control group, model group, and acupuncture group were originally visualized by PCA (Figure 10(a)) but no important clusters among the three groups were found in PCA analysis. A supervised clustering method—PLS-DA—had therefore been carried out for optimal separation and identifying the components that significantly contribute to the division. The PLS-DA assessment showed the major variations between the classes with 0.86 predictive accuracy and 0.96 goodness-of-fit (R2) among the three groups (Figure 10(b)). The classification was based on 99 metabolites with VIP scores of >1.2 (Table 2). Table 2 lists the up and downregulation patterns among the three groups of these metabolites. The metabolic pathway study was conducted using the MetaboAnalyst 5.0, based on the KEGG data of these metabolites, shown in Figure 8. The findings revealed that the most important metabolic pathways relating to the regulation effect of acupuncture were pyrimidine metabolism; alanine, aspartate, and glutamate metabolism; arginine biosynthesis; phenylalanine, tyrosine, and tryptophan biosynthesis; linoleic acid metabolism; D-glutamine and D-glutamate metabolism; taurine and hypotaurine metabolism and phenylalanine metabolism (Figure 11), and six of these pathways were consistent with the PICRUSt analysis prediction (Supplementary Figure S1), except alanine, aspartate, and glutamate metabolism and arginine biosynthesis.

4. Discussion

According to traditional Chinese medicine (TCM) theory, the pathogenesis of AD is closely related to internal organ insufficiency. Qi is the energy that sustains the life system based on the principle of TCM. Qi circulates in specific meridians of the body, and a blockage of Qi circulation will result in organ dysfunction. As a result, acupoints in particular meridians are often chosen to treat illness. The Governor meridian has the ability to collect Qi and facilitate Qi.
circulation through the brain. The Bladder Meridian runs through the brain. Therefore, Baihui acupoints above the Governor meridian; Feishu, Pishu, and Shenshu on the Bladder meridian were used to treat the APP/PS1 mice. Since recent research has linked gut microbiota to AD, Sanyinjiao, Zusanli, and Hegu acupoints on the digestive system related meridians were chosen. Our results indicate that stimulating these acupoints simultaneously has a positive impact on the cognitive ability of the APP/PS1 mice. This result agrees with previous studies [39, 40].

In the MWM study, the performance of mice in the MWM hidden platform training and probe tests after four weeks of acupuncture was comparable to that of the control group, indicating that acupuncture could have a beneficial effect on the spatial learning and memory capacities of the APP/PS1 mice, which is consistent with previous findings [39–41, 46] using AD animal models. In the test of spatial learning capacity based on MWM, the escape latency (Figure 2(b)) and travelled distance (Figure 2(c)) in each group dropped dramatically as learning time increased, demonstrating that after four days of training, each group’s animals had a basic comprehension of the spatial distribution of the water maze. However, the parameter speed (Figure 2(d)) did not reveal such a time-dependent variation. Three groups of animals, excluding the control group, had a reduced swimming speed on the fourth day of training. This could be because the animals are unfamiliar with the maze’s spatial structure during the first three days of training.

Figure 9: Microbial community structures at the family level of mice, and the different groups had substantially different bacterial taxa at the family level. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Through rapid swimming behavior, animals learned how to select the optimal way, resulting in a longer escape time and traveling distance. However, on the fourth day, even if the animals’ swimming speed was decreased, they could rapidly exit the maze via the optimal way. At this point, the slow swimming speed may be explained by the animals having adapted to the water maze’s surroundings and comprehending the maze’s spatial structure. There is no reason to increase one’s swimming speed and attempt the maze’s exit repeatedly. On the other hand, the animals who demonstrated a decreased speed on the third day of training were the C57BL/6 mice, which may be a strain-specific tendency. The more particular mechanism underlying this behavior warrants additional investigation. In the test of spatial memory capacity based on MWM, all parameter values in the acupuncture treatment group were comparable to those in the control group, with no significant difference, indicating that acupuncture had a positive regulatory effect on the memory ability of the APP/PS1 mice.

$A\beta$ plaque and tau protein-containing neurofibrillary tangles are two neuropathological features of AD that are believed to play a role in the neurodegenerative pathway that leads to dementia [53]. $A\beta$ is the main component of senile plaques and a typical pathway product of AD [54], and its overproduction or accumulation is critical to the pathogenesis of AD [55]. Although numerous research on phosphorylated tau (p-tau) alterations in the APP/PS1 mice have been conducted in the past, while the AD Association’s working group considers the total tau (t-tau) and p-tau to be equivalent in determining the disease’s status [56]. As a result, we focused on t-tau changes in our study, which is compatible with the guidelines developed by the AD Association’s work group on AD diagnosis. Tau protein production occurs prior to the onset of degeneration, implying that tau protein is the primary cause of AD neurodegeneration. Acupuncture can reduce the expression of $A\beta$ and tau proteins in the hippocampus, suggesting that the molecular basis of acupuncture in the treatment of AD.

IL-10 is an anti-inflammatory cytokine found in healthy brain tissue, but it is overexpressed in AD patients [57]. IL-10 can promote neuroinflammation and microglia dysfunction, resulting in reducing $A\beta$ clearance, increasing $A\beta$ burden, and cognitive decline [58]. The brains of the IL-10-deficient APP/PS1 mice had a higher number of activated microglia, as well as improved $A\beta$ clearance, reduced $A\beta$ accumulation, and declined modest cognition [59, 60]. Several investigations based on genome-wide association analyses supported our findings, which also showed that IL-10 was increased in the brain of AD [61, 62]. Acupuncture dramatically decreases IL-10 in the APP/PS1 mice, which may reduce $A\beta$ deposition and improve learning and memory.

LPS, as a unique component of Gram-negative bacteria’s outer membrane, is vital in host-pathogen interactions and the innate immune system [63]. LPS is strongly proinflammatory to human neurons, resulting in the production of proinflammatory signals [64], an increase in $A\beta$ [65, 66], and Tau hyperphosphorylation [67, 68]. LPS was identified in significant amounts in the neocortex and hippocampus of the brain during AD [69]. More and more data indicates that LPS can enter the systemic circulation via the portal.
Table 2: List of relevant metabolites identified by VIP scores.

| No | Compound            | VIP scores | KEGG   | M vs. C | A vs. M |
|----|---------------------|------------|--------|---------|---------|
| 1  | 2-Hydroxymyristic acid | 2.3674     | NA     | ↑**     | ↑***    |
| 2  | Cortisol            | 2.2876     | C00735 | ↓        | ↑***    |
| 3  | Costunolide         | 2.1317     | NA     | ↓        | ↑***    |
| 4  | 5-Fluorouridine     | 2.0918     | C16633 | ↓        | ↑***    |
| 5  | Benzyl cinnamate    | 1.9261     | NA     | ↑        | ↓        |
| 6  | 6-Hydroxymelatonin  | 1.9253     | C05643 | ↑        | ↓        |
| 7  | Cymarin             | 1.9074     | NA     | ↑        | ↓        |
| 8  | Pravastatin         | 1.858      | C01844 | ↓        | ↑***    |
| 9  | Ascorbic acid       | 1.8468     | C01041 | ↑        | ↓        |
| 10 | Crotonic acid       | 1.8403     | C01771 | ↓        | ↑**      |
| 11 | Testosterone enanthate | 1.8348   | C08157 | ↑        | ↓*      |
| 12 | D-Serine            | 1.8304     | C00740 | ↓        | ↑**      |
| 13 | Gly-Tyr             | 1.8304     | NA     | ↑        | ↓        |
| 14 | Cholic acid         | 1.8283     | C00695 | ↑        | ↓        |
| 15 | Deoxycholic acid    | 1.8261     | C04483 | ↑        | ↓        |
| 16 | Cotinine            | 1.8094     | NA     | ↑        | ↓**      |
| 17 | L-Methionine sulfoxide | 1.7992 | NA     | ↑        | ↓*      |
| 18 | Acetyl tributyl citrate | 1.7963 | NA     | ↓        | ↑**      |
| 19 | Asiatic acid        | 1.7772     | NA     | ↑        | ↓*      |
| 20 | L(+)-Ornithine      | 1.7701     | NA     | ↑        | ↓***     |
| 21 | Gallic acid         | 1.7472     | C01424 | ↑*       | ↓**      |
| 22 | Mephobarbital       | 1.74       | C07829 | ↑***     | ↓**      |
| 23 | Taurine             | 1.7381     | C00245 | ↑        | ↓**      |
| 24 | Deoxyuridine        | 1.7271     | C00526 | ↑        | ↓**      |
| 25 | 5α-Dihydrotestosterone | 1.7155 | NA     | ↑        | ↓*      |
| 26 | Propionylcarntnine  | 1.7107     | C03017 | ↑        | ↓*      |
| 27 | N6,N6,N6-Trimethyl-L-lysine | 1.7059 | C03793 | ↓        | ↑**      |
| 28 | Tributyl phosphate  | 1.6935     | NA     | ↑        | ↓*      |
| 29 | Desthiobiotin       | 1.6798     | C01909 | ↑**      | ↓**      |
| 30 | Prolylyphenylalanine| 1.6725     | NA     | ↑***     | ↓**      |
| 31 | Jasmonic acid       | 1.6723     | C08491 | ↑        | ↓**      |
| 32 | Glycodeoxycholic acid | 1.6494 | C05464 | ↑        | ↓*      |
| 33 | N-Formylmethionine  | 1.6231     | NA     | ↑        | ↓*      |
| 34 | Thymine             | 1.6229     | C00178 | ↑        | ↓**      |
| 35 | Genistein 4’-O-glucuronide | 1.6162 | NA     | ↑        | ↓**      |
| 36 | Glu-Val-Phe         | 1.5995     | NA     | ↑        | ↓*      |
| 37 | Meprobamate         | 1.5918     | NA     | ↑        | ↓*      |
| 38 | herniarin           | 1.5889     | C09268 | ↓        | ↑**      |
| 39 | Stearamide          | 1.5853     | C13846 | ↓        | ↑*      |
| 40 | Uracil              | 1.5764     | C00106 | ↑        | ↓        |
| 41 | Kahweol             | 1.5601     | NA     | ↓*       | ↑**      |
| 42 | Linoleic acid       | 1.5531     | C01595 | ↑*       | ↓*      |
| 43 | Valylproline        | 1.5507     | NA     | ↑*       | ↓*      |
| No | Compound                        | VIP scores | KEGG      | M vs. C | A vs. M |
|----|--------------------------------|------------|-----------|---------|---------|
| 44 | D-Sphingosine                   | 1.5441     | NA        | ↑       | ↓*      |
| 45 | Eicosapentaenoic acid           | 1.5282     | C06428    | ↑**     | ↓*      |
| 46 | Alanyltyrosine                  | 1.5281     | NA        | ↑       | ↓**     |
| 47 | Monobutylphthalate              | 1.5274     | NA        | ↓       | ↑***    |
| 48 | Hydroxyphenylactic acid         | 1.5262     | C01207    | ↑*      | ↓*      |
| 49 | L-Phenylalanine                 | 1.5259     | C00079    | ↑*      | ↓*      |
| 50 | L-Pyroglutamic acid             | 1.5225     | C01879    | ↑       | ↑**     |
| 51 | Diisobutylphthalate             | 1.5224     | NA        | ↓       | ↑**     |
| 52 | Taurodeoxycholic acid           | 1.5198     | C05463    | ↓       | ↑***    |
| 53 | 2-Methyl-S-benzothiazole        | 1.5025     | NA        | ↓       | ↑***    |
| 54 | Coumarin                        | 1.4947     | C05851    | ↓**     | ↑*      |
| 55 | Perillartine                    | 1.4923     | NA        | ↓       | ↑***    |
| 56 | Asiaticoside                    | 1.4824     | C15428    | ↑       | ↑*      |
| 57 | Oleanolic acid                  | 1.4788     | C17148    | ↑       | ↓*      |
| 58 | Nateglinide                     | 1.4757     | NA        | ↑       | ↓*      |
| 59 | DL-Glutamine                    | 1.4374     | C00303    | ↑       | ↑*      |
| 60 | N-Acetylaspartic acid           | 1.4348     | C01042    | ↑*      | ↓*      |
| 61 | N-Acetyl-L-leucine              | 1.433      | C02710    | ↑       | ↓*      |
| 62 | Gluconolactone                  | 1.4319     | NA        | ↓       | ↑*      |
| 63 | 5-Hydroxy-L-tryptophan          | 1.4087     | NA        | ↓       | ↑*      |
| 64 | Limonene                        | 1.4042     | NA        | ↓       | ↑*      |
| 65 | Glu-Gln                         | 1.394      | NA        | ↓       | ↑*      |
| 66 | Dodecyl sulfate                 | 1.392      | C08031    | ↓**     | ↑*      |
| 67 | Dihydrothymine                  | 1.379      | NA        | ↑       | ↓*      |
| 68 | Gabapentin                      | 1.3722     | D00332    | ↓       | ↑*      |
| 69 | Thiamine                        | 1.3713     | C00378    | ↓       | ↑*      |
| 70 | Arachidonic acid                | 1.3673     | C00219    | ↑**     | ↓*      |
| 71 | Alpha, alpha-Trehalose          | 1.3651     | C01083    | ↑       | ↑*      |
| 72 | 6-Methylquinoline               | 1.3557     | NA        | ↑       | ↓*      |
| 73 | Daidzin                         | 1.3546     | C10216    | ↓       | ↑*      |
| 74 | Gly-Val                         | 1.351      | NA        | ↑       | ↓*      |
| 75 | N5-Acetyllornithine             | 1.3466     | NA        | ↑       | ↓*      |
| 76 | Benzothiazole                   | 1.3405     | NA        | ↑*      | ↑*      |
| 77 | Uridine monophosphate (UMP)     | 1.328      | C00105    | ↑       | ↓**     |
| 78 | L-Aspartic acid                 | 1.3063     | C00049    | ↓       | ↑*      |
| 79 | Crustecdysone                   | 1.3018     | NA        | ↓       | ↓*      |
| 80 | 2,3,4,9-Tetrahydro-1H-beta-carboline-3-carboxylic acid | 1.2957 | NA | ↓ | ↑* |
| 81 | 2,2,6,6-Tetramethyl-1-piperidinol (TEMPO) | 1.2921 | NA | ↓ | ↑* |
| 82 | Imazamox                        | 1.2899     | C18598    | ↓*      | ↓*      |
| 83 | 2,4-Quinolinediol               | 1.2814     | C16716    | ↑       | ↓*      |
| 84 | 5-Thymidylic acid               | 1.2799     | C00364    | ↑*      | ↓*      |
| 85 | Thymidine                       | 1.2671     | C00214    | ↑       | ↓*      |
| 86 | 8-HETE                          | 1.2615     | C14776    | ↑       | ↓*      |
vein and subsequently affected brain tissue, which is a key source of inflammatory deterioration in AD [70]. Our findings revealed that LPS levels in the APP/PS1 model group’s blood were significantly raised and that they might be greatly reduced by acupuncture. This corresponded to prior research findings that acupuncture at Zusanli had been demonstrated to stimulate anti-inflammatory pathways and drastically lower proinflammatory cytokines [71]. Based on the findings, acupuncture may reduce Aβ deposition and tau phosphorylation by lowering LPS levels, and so have a therapeutic effect on AD.

Acupuncture has been explored in recent years to improve gut microbiota [36, 37], signaling that the gut microbiota could be a suitable target for the therapeutic

### Table 2: Continued.

| No | Compound                          | VIP scores | KEGG       | M vs. C | A vs. M |
|----|-----------------------------------|------------|------------|---------|---------|
| 87 | N2,N2-Dimethylguanosine           | 1.2596     | NA         | ↑*      | ↑*      |
| 88 | p-Coumaraldehyde                  | 1.257      | NA         | ↓       | ↑*      |
| 89 | Pyridoxine                        | 1.2569     | NA         | ↓       | ↑*      |
| 90 | Glycyll-L-leucine                 | 1.2534     | C02155     | ↑       | ↓*      |
| 91 | L-Glutamic acid                   | 1.2445     | C00025     | ↓       | ↑       |
| 92 | 5-Hydroxytryptophan               | 1.2438     | C01017     | ↓       | ↑*      |
| 93 | Neocnidilide                      | 1.2399     | NA         | ↑       | ↑       |
| 94 | Isophorone                        | 1.2268     | C14743     | ↓       | ↑       |
| 95 | 6-Hydroxyxcaproic acid            | 1.2208     | NA         | ↑       | ↑*      |
| 96 | Xanthosine                        | 1.2103     | C01762     | ↑       | ↓       |
| 97 | Pentadecanoic acid                | 1.2077     | C16537     | ↑*      | ↓       |
| 98 | Pachyrrhizin                      | 1.2051     | NA         | ↓*      | ↑*      |
| 99 | Prolinamide                       | 1.2024     | C19781     | ↓       | ↑       |

The sequence of the metabolites indicates their importance for the contribution to the group separations. "↑" in M vs. C indicates that specific metabolites in the APP/PS1 model group are upregulated in comparison to the control group. "↓" in M vs. C indicates that specific metabolites in the APP/PS1 model group are downregulated in comparison to the control group. "↑" in A vs. M indicates that specific metabolites in the acupuncture treatment group are upregulated in comparison to the APP/PS1 model group. "↓" in A vs. M indicates that specific metabolites in the acupuncture treatment group are downregulated in comparison to the acupuncture treatment group. "∗" reveals the significant difference of metabolites abundance between the two groups determined by Student’s t-test, ∗∗∗: p < 0.001; ∗∗: p < 0.01; ∗: p < 0.05.

![Figure 11: Bubble plots showing the altered metabolic pathways in mice.](image-url)
effect of acupuncture. Atypical gut microbiota has been observed in some AD investigations [20–27]. As a result, we focused on the changes in the gut microbiota of AD model mice. According to our research, the gut microbiota of the APP/PS1 mice changed dramatically. The gut ecology of the APP/PS1 mice had been demonstrated to be altered by acupuncture. The APP/PS1 mice had a lower diversity of gut microbiota, but acupuncture appeared to boost gut microbiota diversity (Figure 5). The concentration of germs on phylum and family levels was comparable in the acupuncture treatment group and APP/PS1 model group. At the phylum level, Bacteroides and Firmicutes had the highest relative abundance. The model group had the largest relative abundance of Actinobacteria, which differs significantly from the control and acupuncture treatment groups (Figure 6). Previous research revealed an increase in the relative abundance of Actinobacteria in the feces of the APP/PS1 mice and AD patients [72–74]. Actinobacteria secretes chemotactic and proinflammatory cytokine-inducing proteins, activates complement pathways, and generates hyaluronidasises, proteases, and neuraminidasises, all of which are expected to induce epithelial permeabilization and inflammatory infiltration [75]; therefore, Actinobacteria may contribute to the advancement of AD. According to our findings, acupuncture may have a therapeutic effect on AD by lowering abundance of Actinobacteria.

At the family level, the relative abundance of Porphyromonadaceae [76] and Helicobacteraceae [77] was shown to be quite high in the APP/PS1 mice, which was consistent with earlier findings. Many Porphyromonadaceae species are part of the indigenous microbiota of the human and animal gastrointestinal tract and oral cavity; however, some have been linked to a variety of human and animal infections [78]. The increased Helicobacteraceae expression was primarily owing to the increased Helicobacter. Infection with pathogenic microorganisms such as Helicobacter pylori can worsen Aβ development and Tau phosphorylation, increasing the likelihood of AD [79, 80]. Acupuncture dramatically reduced the amount of Porphyromonadaceae and Helicobacteraceae in this study, indicating that the gut microbiota components impacted by acupuncture may interfere with AD.

In this study, we also discovered that the quantity of Bacteroidaceae was low in the APP/PS1 mice, which was consistent with earlier findings [73, 81]. Bacteroidaceae expression declined predominantly as a result of a fall in Bacteroides quantity. Previous research found low levels of Bacteroidaceae in patients with cognitive impairment and brain amyloidosis [82]. Acupuncture significantly increased the amount of Bacteroidaceae in this study, showing that acupuncture may have a therapeutic effect on AD by altering intestinal flora.

Acupuncture increased the expression of Lactobacillaceae to some level in this study. Lactobacillaceae overgrowth has already been documented in the APP/PS1 mice [83, 84]. Lactobacillaceae is a Firmicutes phylum family of Gram-positive, non-spore-forming, fermentative bacteria that are generally thought to be helpful to humans. The main reason for the increase in Lactobacillaceae in this study was an increase in Lactobacillus relative abundance. Lactobacillus has been found in AD rats to improve memory and learning problems [85]. Simultaneously, human investigations have revealed that the concentration of Lactobacillus is related to age [86]. These data imply that Lactobacillus plays an important role in the development of AD. According to Wang et al., Lactobacillus may improve cognitive impairment caused by prolonged stress in rats [87]. Lactobacillus fermentum NS9 treatment increased memory ability [88].

Metabolites produced by host and intestinal bacteria exert important and diverse effects on various diseases including AD [89]. Acupuncture modified a huge number of metabolites in the APP/PS1 mice’s feces, according to our findings. The VIP score was used to investigate the altered metabolites, and then, the KEGG metabolic pathway was examined. PICRUSt study targeting the quantity of gut microbiota discovered six metabolic pathways that were compatible with the KEGG pathway predicted results. These six pathways have been linked to the occurrence, development, and treatment of neurodegenerative disorders in previous studies [90–94]. This shows that acupuncture-induced changes in gut flora and metabolites may alter the learning and memory abilities of the APP/PS1 mice in this research. It is important to remember that acupuncture is a holistic and systemic treatment. Acupuncture has the ability to influence not only the number of intestinal microorganisms but also metabolites, allowing it to govern the biological system as a whole. As a result, when paired with intestinal flora and metabolites to research the effect of acupuncture, the intervention effect of acupuncture on AD may be revealed more fully. However, in this study, we employed nontargeted metabolomics technology to detect metabolites, which, on the one hand, extended the types of metabolites, but on the other hand, rendered our metabolites insufficient to focus on specific metabolic pathways, such as the bile acid metabolic pathway. Future research could look at employing a targeted metabolomics platform to explore specific metabolite pathways in order to give more reliable biological evidence for the effect of acupuncture intervention on AD.

5. Conclusions

In this study, acupuncture was demonstrated to improve the learning and memory ability of the APP/PS1 mice. Acupuncture may lower Aβ deposition and t-tau protein content in the brain hippocampus of the APP/PS1 mice, control inflammatory factor release, and alter intestinal flora and metabolites. Therefore, acupuncture, as a holistic therapy, has the potential to significantly contribute in the treatment and control of AD. Gut dysregulation and intestinal microbial-host interaction now play a major role in neurodegenerative illness, according to growing experimental and clinical evidence. While several promising biomarkers were discovered in our study, more research into how to use these biomarkers to examine the therapeutic effects of acupuncture on AD are required. Methods of changing the composition of the microbiome through acupuncture
require further research. In conclusion, this study adds to our understanding of the effect of acupuncture on AD and opens the door to further research into the alterations of intestinal bacteria in the presence of AD.

**Data Availability**

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethical Approval**

The study was approved by the Institutional Animal Ethics Committee of Changchun Wish Technology Service Co., Ltd. ( Permit number: 20200811-01; approval date: 7 August 2020).

**Conflicts of Interest**

All authors declare that they have no competing interests.

**Authors’ Contributions**

B. Y. and Z.C. were responsible for the conceptualization; M. H. and B. Y. were responsible for the methodology; X.Z. and B. Y. were responsible for the validation; X.C., T.P., and Q.G. were responsible for the formal analysis; Y.Z. and X.X. were responsible for the resources; B. Y., Z. J., and X.C. were responsible for writing and preparing the original draft; B. Y., M.S., Z. J., and Z.C. were responsible for writing, reviewing, and editing the manuscript; Z.C. was responsible for the supervision; Y.Z., X.C., and Z.C. were responsible for funding acquisition. All authors have read and agreed to the published version of the manuscript. Bo Yang and Min He contributed equally to this work.

**Acknowledgments**

The authors acknowledge Mr. Dawei Zhang for his help in the animal experiment. This work was supported by the "Natural Science Foundation of Jilin Province Science and Technology Development Plan Project (No. 20190201147C)", the "Open Fund Project of the Key Laboratory of the Ministry of Education of China (No. zy2x1708)", the "National Natural Science Foundation of China (No. 81674078)", the "Scientific and Technological Developing Project of Jilin Province (No. YDZJ202101ZYS119)", the "Science and Technology Research Project of Jilin Provincial Department of Education (No. JJKH20210986KJ)" and the "Key Research and Development Project of Shaanxi Province (No. 2017ZDXM-SF-017)."

**Supplementary Materials**

Figure S1: the supplementary material depicts the effects among different groups of microbiota data predicted by PICRUSt analysis. (Supplementary Materials)

**References**

[1] J. M. Long and D. M. Holtzman, “Alzheimer disease: an update on pathobiology and treatment strategies,” Cell, vol. 179, no. 2, pp. 312–339, 2019.

[2] S. Park, J. H. Lee, and E. J. Yang, “Effects of acupuncture on Alzheimer’s disease in animal-based research,” Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 6512520, 5 pages, 2017.

[3] Z. Arvanitakis, R. C. Shah, and D. A. Bennett, “Diagnosis and management of dementia: review,” JAMA, vol. 322, no. 16, pp. 1589–1599, 2019.

[4] F. Zhang, R. J. Zhong, C. Cheng, S. Li, and W. D. Le, “New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease,” Acta Pharmacologica Sinica, vol. 42, 2021.

[5] J. Y. Y. Szeto and S. J. G. Lewis, “Current treatment options for Alzheimer's disease and Parkinson's disease dementia,” Current Neuropharmacology, vol. 14, no. 4, pp. 326–338, 2016.

[6] G. Livingston, A. Sommerlad, V. Orgeta et al., “Dementia prevention, intervention, and care,” Lancet, vol. 390, no. 10113, pp. 2673–2734, 2017.

[7] S. Schwarz, L. Froelich, and A. Burns, “Pharmacological treatment of dementia,” Psychiatry, vol. 25, no. 6, pp. 542–550, 2012.

[8] A. K. Desai and G. T. Grossberg, “Diagnosis and treatment of Alzheimer’s disease,” Neurology, vol. 64, no. 12, suppl 3, pp. S34–S39, 2005.

[9] Z. Wang, P. Liang, Z. Zhao et al., “Acupuncture modulates resting state hippocampal functional connectivity in Alzheimer disease,” PLoS One, vol. 9, no. 3, 2014.

[10] C. Takizawa, P. L. Thompson, A. Van Walsem, C. Faure, and W. C. Maier, "Epidemiological and economic burden of Alzheimer’s disease: a systematic literature review of data across Europe and the United States of America," Journal of Alzheimer's Disease, vol. 43, no. 4, pp. 1271–1284, 2015.

[11] Y. J. Jung, Y. H. Kim, M. Bhalla, S. B. Lee, and J. Seo, "Genomics: new light on Alzheimer’s disease research," International Journal of Molecular Sciences, vol. 19, no. 12, 2018.

[12] L. Yu, V. A. Petyuk, C. Gaiteri et al., "Targeted brain proteomics uncover multiple pathways to Alzheimer’s dementia," Annals of Neurology, vol. 84, no. 1, pp. 78–88, 2018.

[13] J. M. Wilkins and E. Trushina, "Application of metabolomics in Alzheimer’s disease’s," Frontiers in Neurology, vol. 8, 2017.

[14] N. Chandra, A. Srivastava, and S. Kumar, "Bacterial biofilms in human gastrointestinal tract: an intricate balance between health and inflammatory bowel diseases," World Journal of Pharmacology, vol. 8, no. 3, pp. 26–40, 2019.

[15] R. Ding, W. Goh, R. Wu et al., "Revisit gut microbiota and its impact on human health and disease," Analysis, vol. 27, no. 3, pp. 623–631, 2019.

[16] A. V. Vila, F. Imhann, V. Collij et al., "Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome," Science Translational Medicine, vol. 10, no. 472, 2018.
[17] F. Frost, T. Kacprowski, M. Rühlemann et al., “Impaired exocrine pancreatic function associates with changes in intestinal microbiota composition and diversity,” Gastroenterology, vol. 156, no. 4, pp. 1010–1015, 2019.
[18] A. Kurilshikov, I. C. L. van den Munckhof, L. Chen et al., “Gut microbial associations to plasma metabolites linked to cardiovascular phenotypes and risk,” Circulation Research, vol. 24, no. 12, pp. 1808–1820, 2019.
[19] C. O. Neill, “Gut microbes metabolize Parkinson’s disease drug,” Science, vol. 364, no. 6445, pp. 1030-1031, 2019.
[20] A. Varesi, E. Pierella, M. Romeo et al., “The potential role of gut microbiota in Alzheimer’s disease: from diagnosis to treatment,” Nutrients, vol. 14, no. 3, p. 668, 2022.
[21] D. Goyal, S. A. Ali, and R. K. Singh, “Emerging role of gut microbiota in modulation of neuroinflammation and neurodegeneration with emphasis on Alzheimer’s disease,” Progress in Neuropsychopharmacology & Biological Psychiatry, vol. 106, 2021.
[22] S. Liu, J. Gao, M. Q. Zhu, K. D. Liu, and H. L. Zhang, “Gut microbiota and dysbiosis in Alzheimer’s disease: implications for pathogenesis and treatment,” Molecular neurobiology, vol. 57, no. 12, pp. 5026–5043, 2020.
[23] M. Douliberis, G. Kotronis, D. Gialamprinou et al., “Alzheimer’s disease and gastrointestinal microbiota; impact of Helicobacter pylori infection involvement,” International Journal of Neuroscience, vol. 131, no. 3, pp. 289–301, 2021.
[24] P. Kesika, N. Suganthy, B. S. Sivamaruthi, and C. Chaiyasut, “Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer’s disease,” Life Sciences, vol. 264, 2021.
[25] C. C. Hung, C. C. Chang, C. W. Huang, R. Nouchi, and C. H. Cheng, “Gut microbiota in patients with Alzheimer’s disease spectrum: a systematic review and meta-analysis,” Aging (Albany NY), vol. 14, pp. 477–496, 2022.
[26] J. P. Haran, S. K. Bhattacharai, S. E. Foley et al., “Alzheimer’s disease microbe is associated with dysregulation of the anti-inflammatory P-glycoprotein pathway,” mBio, vol. 10, no. 3, 2019.
[27] M. Zhang, D. Zhao, G. H. Zhou, and C. B. Li, “Dietary pattern, gut microbiota, and Alzheimer’s disease,” Journal of agricultural and food chemistry, vol. 68, no. 46, pp. 12800–12809, 2020.
[28] X.-R. Wang, G.-X. Shi, J.-W. Yang et al., “Acupuncture ameliorates cognitive impairment and hippocampus neuronal loss in experimental vascular dementia through Nrf 2-mediated antioxidant response,” Free Radical Biology & Medicine, vol. 89, pp. 1077–1084, 2015.
[29] D. Forbes, S. C. Forbes, C. M. Blake, E. J. Thiessen, and S. Forbes, “Exercise programs for people with dementia,” The Cochrane database of systematic reviews, vol. 4, article CD00664, 2015.
[30] M. S. Lee, B.-C. Shin, and E. Ernst, “Acupuncture for Alzheimer’s disease: a systematic review,” International Journal of Clinical Practice, vol. 63, no. 6, pp. 874–879, 2009.
[31] R. B. Kelly and J. Willis, “Acupuncture for pain,” American Family Physician, vol. 100, no. 2, pp. 89–96, 2019.
[32] L. Lu, X. G. Zhang, L. L. D. Zhong et al., “Acupuncture for neurogenesis in experimental ischemic stroke: a systematic review and meta-analysis,” Scientific reports, vol. 6, no. 1, 2016.
[33] Y. M. Chen, X. L. Xie, P. Y. Xiao et al., “Acupuncture on treating asthma,” Medicine (Baltimore), vol. 99, no. 1, p. e18457, 2020.
[34] G. Q. Song, C. Fiocchi, and J. P. Achkhar, “Acupuncture in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 25, no. 7, pp. 1129–1139, 2019.
[35] W. Tan and S. C. Lin, “Research progress on the mechanism of acupuncture and moxibustion in treating Alzheimer’s disease,” Mod Tradit Chin Me Mater Med-World Sci Technol, vol. 22, pp. 2621–2627, 2020.
[36] W. D. Lu, E. D. Clower, A. D. Gilman, and D. S. Rosenthal, “The value of acupuncture in cancer care,” Hematology/Oncology Clinics of North America, vol. 22, pp. 631–648, 2008.
[37] E. Dean-Clower, A. M. Doherty-Gilman, A. Keshaviah et al., “Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients,” Integrative Cancer Therapies, vol. 9, no. 2, pp. 158–167, 2010.
[38] S. P. Vinjamury, J. T. Li, E. Hsiao et al., “Effects of acupuncture for cancer pain and quality of life - a case series,” Chinese Medicine, vol. 8, 2013.
[39] X. Li, F. Guo, Q. Zhang et al., “Electroacupuncture decreases cognitive impairment and promotes neurogenesis in the APP/PS1 transgenic mice,” BMC Complementary and Alternative Medicine, vol. 14, no. 37, 2014.
[40] J. Cao, Y. S. Tang, Y. J. Li, K. Gao, X. D. Shi, and Z. G. Li, “Behavioral changes and hippocampus glucose metabolism in APP/PS1 transgenic mice via electro-acupuncture at governor vessel acupoints,” Frontiers in Aging Neuroscience, vol. 9, 2017.
[41] X. Wang, Y. Miao, J. Abulizi et al., “Improvement of electroacupuncture on APP/PS1 transgenic mice in spatial learning and memory probably due to expression of Aβ<β<β/> and LRPI in hippocampus,” Evidence-based complementary and alternative medicine: eCAM, vol. 2016, article 7603975, p. 1, 2016.
[42] C. Grienberger, N. L. Rochefort, H. Adelsberger et al., “Staged decline of neuronal function in vivo in an animal model of Alzheimer’s disease,” Nature Communications, vol. 3, 2012.
[43] A. D. Keskim, M. Kekus, H. Adelsberger et al., “BACE inhibition dependent repair of Alzheimer’s pathophysiology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 32, pp. 8631–8636, 2017.
[44] R. Radde, T. Bolmont, S. A. Kaeser et al., “Abeta 42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology,” EMBO reports, vol. 7, no. 9, pp. 940–946, 2006.
[45] S. A. Ferguson, S. Sarkar, and L. C. Schmued, “Longitudinal behavioral changes in the APP/PS1 transgenic Alzheimer’s disease model,” Behavioural Brain Research, vol. 242, pp. 125–134, 2013.
[46] W. Liu, P. Zhuo, L. Li et al., “Activation of brain glucose metabolism ameliorating cognitive impairment in APP/PS1 transgenic mice by electroacupuncture,” Free Radical Biology and Medicine, vol. 112, no. 7, pp. 174–190, 2017.
[47] J. Ma, Y. Gao, L. Jiang et al., “Fluoxetine attenuates the impairment of spatial learning ability and prevents neuron loss in middle-aged APPswe/PSEN1dE9 double transgenic Alzheimer’s disease mice,” Oncotarget, vol. 8, no. 17, pp. 27676–27692, 2017.
[48] M. G. Langille, J. Zaneveld, J. G. Caporaso et al., “Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences,” Nature biotechnology, vol. 31, no. 9, pp. 814–821, 2013.
[49] M. Kanehisa, S. Goto, Y. Sato, M. Furumichi, and M. Tanabe, “KEGG for integration and interpretation of large-scale
molecular data sets,” Nucleic acids research, vol. 40, no. D1, pp. D109–D114, 2012.

[50] D. H. Parks, G. W. Tyson, P. Hugenholtz, and R. G. Beiko, “STAMP: statistical analysis of taxonomic and functional profiles,” Bioinformatics, vol. 30, no. 21, pp. 3123–3124, 2014.

[51] P. T. Nelson, G. A. Jicha, F. A. Schmitt et al., “Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles’ do count’ when staging disease severity,” Journal of Neuropathology and Experimental Neurology, vol. 66, no. 12, pp. 1136–1146, 2007.

[52] J. W. Kinney, S. M. Bemiller, A. S. Murtishaw, A. M. Leisgang, A. M. Salazar, and B. T. Lamb, “Inflammation as a central mechanism in Alzheimer's disease,” Alzheimers & Dementia, vol. 4, pp. 575–590, 2018.

[53] R. La Joie, A. V. Visani, S. L. Baker et al., “Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET,” Science Translational Medicine, vol. 12, no. 524, article eaau5732, 2020.

[54] G. K. Gouras, J. Tsai, J. Naslund et al., “Intraneuronal Aβ42 accumulation in human brain,” The American Journal of pathology, vol. 156, no. 1, pp. 15–20, 2000.

[55] I. K. Martikainen, N. Kemppainen, J. Johansson et al., “Brain β-amyloid and atrophy in individuals at increased risk of cognitive decline,” AJNR American Journal of Neuroradiology, vol. 40, no. 1, pp. 80–85, 2019.

[56] M. K. GM, D. S. Knopman, H. Chertkow et al., “The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease,” Alzheimer's & Dementia: The Journal of the Alzheimer's Association, vol. 7, no. 3, pp. 263–269, 2011.

[57] A. M. Szczepaniak, S. Funes, W. Petko, and G. E. Ringheim, “IL-4, IL-10 and IL-13 modulate A beta (1–42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line,” Journal of neuroimmunology, vol. 113, no. 1, pp. 49–62, 2001.

[58] J. P. Michaud and S. Rivest, “Anti-inflammatory signaling in microglia exacerbates Alzheimer's disease-related pathology,” Neuron, vol. 85, no. 3, pp. 450–452, 2015.

[59] C. K. Glass, K. Saijo, B. Winner, M. C. Marchetto, and F. H. Gage, “Mechanisms underlying inflammation in neurodegeneration,” Cell, vol. 140, no. 6, pp. 918–934, 2010.

[60] M. V. Guillot-Sestier, K. R. Doty, D. Gate et al., “IL10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology,” Neuron, vol. 85, no. 3, pp. 534–548, 2015.

[61] X. Z. Li, J. T. Long, T. G. He, R. Belshaw, and J. Scott, “Integrated genomic approaches identify major pathways and upstream regulators in late onset Alzheimer's disease,” Scientific reports, vol. 5, article 12393, 2015.

[62] B. Zhang, C. Gaiter, L. G. Bodea et al., “Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease,” Cell, vol. 153, no. 3, pp. 707–720, 2013.

[63] R. F. Maldonado, I. Sá-Correia, and M. A. Valvano, “Lipopolysaccharide modification in Gram-negative bacteria during chronic infection,” FEMS microbiology reviews, vol. 40, no. 3, pp. 480–493, 2016.

[64] W. J. Lukíw, “Bacteroides fragilis lipopolysaccharide and inflammatory signaling in Alzheimer’s disease,” Frontiers in Microbiology, vol. 7, article 1544, 2016.

[65] Y. Zhao, H. Zhao, N. Lobo, X. Y. Guo, S. M. Gentleman, and D. Q. Ma, “Cestalrol enhances cell viability and inhibits amyloid-β production induced by lipopolysaccharide in vitro,” Journal of Alzheimers Disease, vol. 41, no. 3, pp. 835–844, 2014.

[66] D. Wu, X. Zhang, M. Zhao, and A. L. Zhou, “The role of the TLR4/NF-κB signaling pathway in Aβ accumulation in primary hippocampal neurons,” Sheng Li Xue Bao, vol. 67, no. 3, pp. 319–328, 2015.

[67] M. Kitazawa, S. Oddo, T. R. Yamasaki, K. N. Green, and F. LaFerla, “Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease,” The Journal of neuroscience: the official journal of the Society for Neuroscience, vol. 25, no. 39, pp. 8843–8853, 2005.

[68] J. Liu, D. Wang, S. Q. Li, Y. Yu, and R. D. Ye, “Suppression of LPS-induced tau hyperphosphorylation by serum amyloid A,” Journal of Neuroinflammation, vol. 13, no. 1, article 28, 2016.

[69] Y. H. Zhao, V. Jaber, and W. J. Lukíw, “Secretory products of the human GI tract microbiome and their potential impact on Alzheimer's disease (AD): detection of lipopolysaccharide (LPS) in AD hippocampus,” Frontiers in cellular and infection microbiology, vol. 7, article 318, 2017.

[70] J. Lu, P. Guo, X. Liu et al., “Herbal formula Fo Shou San attenuates Alzheimer’s disease-related pathways via the gut-liver-brain axis in APP/PS1 mouse model of Alzheimer's disease,” Evidence-based complementary and alternative medicine: eCAM, vol. 2019, article 8302950, p. 1, 2019.

[71] Q. Song, S. Hu, H. B. Wang et al., “Electroacupuncture at Zusani point (ST36) attenuates pro-inflammatory cytokine release and organ dysfunction by activating cholinergic anti-inflammatory pathway in rat with endotoxin challenge,” African journal of traditional, complementary, and alternative medicines: AJTMCAM, vol. 11, no. 2, pp. 469–474, 2014.

[72] T. Harach, N. Marungruang, N. Duthilleul et al., “Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota,” Scientific reports, vol. 7, no. 1, article 41802, 2017.

[73] Z. Q. Zhuang, L. L. Shen, W. W. Li et al., “Gut microbiota is altered in patients with Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 63, no. 4, pp. 1337–1346, 2018.

[74] F. Q. Zhu, C. R. Li, F. N. Chu, X. P. Tian, and J. Zhu, “Target dysbiosis of gut microbes as a future therapeutic manipulation in Alzheimer's disease,” Frontiers in aging neuroscience, vol. 12, article 544235, 2020.

[75] A. M. Bhata, J. F. Maisonneuve, and D. H. Persing, “Propionobacterium acnes and chronic diseases,” in The Infectious Etiology of Chronic Diseases: Defining the Relationship, Enhancing the Research, and Mitigating the Effects, S. L. Knobler, S. O'Connor, S. M. Lemon, and M. Najafi, Eds., pp. 74–80, Corixa Corporation, Seattle, America, 2004.

[76] Z. H. Zhuang, R. T. Yang, W. X. Wang, L. Qi, and T. Huang, “Associations between gut microbiota and Alzheimer's disease, major depressive disorder, and schizophrenia,” Journal of Neuroinflammation, vol. 17, no. 1, p. 288, 2020.

[77] L. Shen, L. Liu, and H. F. Ji, “Alzheimer's disease histological and behavioral manifestations in transgenic mice correlate with specific gut microbiome state,” Journal of Alzheimer's Disease, vol. 56, no. 1, pp. 385–390, 2017.

[78] E. Rosenberg, E. DeLong, S. Lory, and E. Stackebrandt, “Other major lineages of bacteria and the archaea,” in The
Prokaryotes, F. Thompson, Ed., pp. 811–824, Springer-Verlag, Berlin Heidelberg, Germany, 2014.

[79] X. L. Wang, J. Zeng, J. Feng et al., "Helicobacter pylori filtrate impairs spatial learning and memory in rats and increases \( \beta \)-amyloid by enhancing expression of presenilin-2," Frontiers in Aging Neuroscience, vol. 6, p. 66, 2014.

[80] X. L. Wang, J. Zeng, Y. Yang et al., "Helicobacter pylori filtrate induces Alzheimer-like tau hyperphosphorylation by activating glycogen synthase kinase-3\( \beta \)," Journal of Alzheimer’s Disease, vol. 43, no. 1, pp. 153–165, 2014.

[81] Z. Z. Sun, X. Y. Li, S. Wang, L. Shen, and H. F. Ji, "Bidirectional interactions between curcumin and gut microbiota in transgenic mice with Alzheimer’s disease," Applied microbiology and biotechnology, vol. 104, no. 8, pp. 3507–3515, 2020.

[82] A. Cattaneo, N. Cattane, S. Galluzzi et al., "Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly," Neurobiology of Aging, vol. 49, pp. 60–68, 2017.

[83] E. Y. Hsiao, S. W. McBride, S. Hsien et al., "Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders," Cell, vol. 155, no. 7, pp. 1451–1463, 2013.

[84] L. Zhang, Y. Wang, X. Xiayu et al., "Altered gut microbiota in a mouse model of Alzheimer’s disease," Journal of Alzheimer’s Disease, vol. 60, no. 4, pp. 1241–1257, 2017.

[85] M. J. Claesson, I. B. Jefferry, S. Conde et al., "Gut microbiota composition correlates with diet and health in the elderly," Nature, vol. 488, no. 7410, pp. 178–184, 2012.

[86] S. Liang, T. Wang, X. Hu et al., "Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress," Neuroscience, vol. 310, pp. 561–577, 2015.

[87] T. Wang, X. Hu, S. Liang et al., "Lactobacillus fermentum NS9 restores the antibiotic induced physiological and psychological abnormalities in rats," Beneficial Microbes, vol. 6, no. 5, pp. 707–717, 2015.

[88] L. Wu, Y. Q. Han, Z. P. Zheng et al., "Altered gut microbial metabolites in amnestic mild cognitive impairment and Alzheimer’s disease: signals in host–microbe interplay," Nutrients, vol. 13, no. 1, article 228, 2021.

[89] T. Udhayabanu, A. Manole, M. Rajeshwari, P. Varalakshmi, H. Houlden, and B. Ashokkumar, "Riboflavin responsive mitochondrial dysfunction in neurodegenerative diseases," Journal of Clinical Medicine, vol. 6, no. 5, article 52, 2017.

[90] K. Xie, Q. Qin, Z. P. Long et al., "High-throughput metabolomics for discovering potential biomarkers and identifying metabolic mechanisms in aging and Alzheimer’s disease," Frontiers in Cell and Developmental Biology, vol. 9, article 602887, 2021.

[91] C. Madeira, C. Vargas-Lopes, O. C. Brandão et al., "Elevated glutamate and glutamine levels in the cerebrospinal fluid of patients with probable Alzheimer’s disease and depression," Frontiers in Psychiatry, vol. 9, p. 561, 2018.

[92] S. Liang, T. Wang, X. Hu et al., "Altered gut microbiota in a mouse model of Alzheimer’s disease," Journal of Alzheimer’s Disease, vol. 60, no. 4, pp. 1241–1257, 2017.